Abstract：
OBJECTIVE: To describe and report the outcomes of doxycycline sclerotherapy in patients with periorbital lymphatic malformations(LMs).
METHODS: A retrospective review of consecutive patients diagnosed with periorbital LMs and who received doxycycline sclerotherapy at Hong Kong Eye Hospital and Queen Elizabeth Hospital, Hong Kong between January 2016 and June 2022. Doxycycline was prepared with a concentration of 100 mg diluted in 10 mL water for injection. A 23-gauge needle aiming at the center of the macrocyst was used to aspirate fluid from the lesion; this was then followed by an intralesional injection of 0.5 to 2 ml of doxycycline depending on the size of the cavity.
RESULTS: A total of eight patients(six females) were included in this study. All of them received doxycycline sclerotherapy for periorbital LMs(five extraconal, three intraconal). The median age for receiving sclerotherapy was 29 years old. Seven patients had macrocystic LMs, and one had mixed macro- and microcystic LM. Two of the LMs had venous components radiologically. The average number of sclerotherapy treatment in one patient was 1.4 ± 0.7times. Seven of the eight patients had excellent response radiologically or clinically. One patient showed a satisfactory response after three cycles of sclerotherapy. No recurrence was experienced at median follow-up of 14 months. None of the patients experienced visual threatening or systemic complication.
CONCLUSIONS: Our preliminary experience with doxycycline sclerotherapy has shown encouraging results for the treatment of macrocystic or mixed-type periorbital LMs, with a favourable safety profile. Further clinical trials with longer follow-ups are warranted on this topic.
METHODS: A retrospective review of consecutive patients diagnosed with periorbital LMs and who received doxycycline sclerotherapy at Hong Kong Eye Hospital and Queen Elizabeth Hospital, Hong Kong between January 2016 and June 2022. Doxycycline was prepared with a concentration of 100 mg diluted in 10 mL water for injection. A 23-gauge needle aiming at the center of the macrocyst was used to aspirate fluid from the lesion; this was then followed by an intralesional injection of 0.5 to 2 ml of doxycycline depending on the size of the cavity.
RESULTS: A total of eight patients(six females) were included in this study. All of them received doxycycline sclerotherapy for periorbital LMs(five extraconal, three intraconal). The median age for receiving sclerotherapy was 29 years old. Seven patients had macrocystic LMs, and one had mixed macro- and microcystic LM. Two of the LMs had venous components radiologically. The average number of sclerotherapy treatment in one patient was 1.4 ± 0.7times. Seven of the eight patients had excellent response radiologically or clinically. One patient showed a satisfactory response after three cycles of sclerotherapy. No recurrence was experienced at median follow-up of 14 months. None of the patients experienced visual threatening or systemic complication.
CONCLUSIONS: Our preliminary experience with doxycycline sclerotherapy has shown encouraging results for the treatment of macrocystic or mixed-type periorbital LMs, with a favourable safety profile. Further clinical trials with longer follow-ups are warranted on this topic.
摘要：
目的：描述和报告多西环素硬化治疗眶周淋巴管畸形（LMs）的结果。
方法:回顾性分析在香港眼科医院及伊利沙伯医院接受多西环素硬化治疗的连续诊断为眶周LMs的病人,香港2016年1月至2022年6月。制备多西环素,其浓度为100mg,稀释于10mL注射用水中。使用瞄准大囊肿中心的23号针从病变中抽出液体；然后根据腔的大小，在病灶内注射0.5至2ml多西环素。
结果：本研究共纳入8名患者（6名女性）。他们都接受了强力霉素硬化疗法治疗眶周LMs（五个外，三个内嵌式)。接受硬化治疗的中位年龄为29岁。七名患者患有大囊性LMs，其中一人患有混合的大囊性和微囊性LM。其中两个LM在放射学上具有静脉成分。1例患者接受硬化治疗的平均次数为1.4±0.7次。八名患者中有七名在放射学或临床上反应良好。经过三个周期的硬化治疗，一名患者表现出令人满意的反应。中位随访14个月时无复发。没有患者出现视觉威胁或全身并发症。
结论：我们使用多西环素硬化疗法的初步经验表明，对于治疗大囊性或混合型眶周LMs，具有良好的安全性。关于这个主题，需要进一步的临床试验和更长时间的随访。
方法:回顾性分析在香港眼科医院及伊利沙伯医院接受多西环素硬化治疗的连续诊断为眶周LMs的病人,香港2016年1月至2022年6月。制备多西环素,其浓度为100mg,稀释于10mL注射用水中。使用瞄准大囊肿中心的23号针从病变中抽出液体；然后根据腔的大小，在病灶内注射0.5至2ml多西环素。
结果：本研究共纳入8名患者（6名女性）。他们都接受了强力霉素硬化疗法治疗眶周LMs（五个外，三个内嵌式)。接受硬化治疗的中位年龄为29岁。七名患者患有大囊性LMs，其中一人患有混合的大囊性和微囊性LM。其中两个LM在放射学上具有静脉成分。1例患者接受硬化治疗的平均次数为1.4±0.7次。八名患者中有七名在放射学或临床上反应良好。经过三个周期的硬化治疗，一名患者表现出令人满意的反应。中位随访14个月时无复发。没有患者出现视觉威胁或全身并发症。
结论：我们使用多西环素硬化疗法的初步经验表明，对于治疗大囊性或混合型眶周LMs，具有良好的安全性。关于这个主题，需要进一步的临床试验和更长时间的随访。
